GH

Guardant Health, Inc. Common Stock

88.01

USD

GH Earnings Reports

Positive Surprise Ratio

GH beat 13 of 30 last estimates.

43%

Next Report

Date of Next Report

Apr 28, 2026

Estimate for Q1 26 (Revenue/ EPS)

$288.22M

-$0.78

Implied change from Q4 25 (Revenue/ EPS)

+2.47%

-22.00%

Implied change from Q1 25 (Revenue/ EPS)

+41.65%

-4.88%

Guardant Health, Inc. Common Stock earnings per share and revenue

On Feb 19, 2026, GH reported earnings of -1.00 USD per share (EPS) for Q4 25, missing the estimate of -0.72 USD, resulting in a -38.56% surprise. Revenue reached 281.27 million, compared to an expected 279.14 million, with a 0.76% difference. The market reacted with a -2.36% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 23 analysts forecast an EPS of -0.78 USD, with revenue projected to reach 288.22 million USD, implying an decrease of -22.00% EPS, and increase of 2.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Guardant Health, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Guardant Health, Inc. Common Stock reported EPS of -$1.00, missing estimates by -38.56%, and revenue of $281.27M, 0.76% above expectations.

How did the market react to Guardant Health, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -2.36%, changed from $110.17 before the earnings release to $107.57 the day after.

When is Guardant Health, Inc. Common Stock expected to report next?

The next earning report is scheduled for Apr 28, 2026.

What are the forecasts for Guardant Health, Inc. Common Stock's next earnings report?

Based on 23 analysts, Guardant Health, Inc. Common Stock is expected to report EPS of -$0.78 and revenue of $288.22M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.